These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33475149)

  • 1. Apremilast in treatment of palmoplantar pustulosis - a case series.
    Kt S; Thakur V; Narang T; Dogra S; Handa S
    Int J Dermatol; 2021 Jun; 60(6):e247-e248. PubMed ID: 33475149
    [No Abstract]   [Full Text] [Related]  

  • 2. [Apremilast in the treatment of palmoplantar pustulosis : A case series].
    Frischhut N; Ratzinger G
    Hautarzt; 2021 Mar; 72(3):252-256. PubMed ID: 32876701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refractory palmoplantar pustulosis succesfully treated with apremilast.
    Carrascosa de Lome R; Conde Montero E; de la Cueva Dobao P
    Dermatol Ther; 2020 Mar; 33(2):e13230. PubMed ID: 31981290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Treatment of Palmoplantar Pustulosis With Apremilast.
    Dorgham N; Crasto D; Skopit S
    J Drugs Dermatol; 2021 Nov; 20(11):1255-1256. PubMed ID: 34784120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
    Wilsmann-Theis D; Kromer C; Gerdes S; Linker C; Magnolo N; Sabat R; Reich K; Mössner R
    J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2045-2050. PubMed ID: 34077577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Use of Tildrakizumab for Treatment of Palmoplantar Pustulosis: A Case Report.
    Del Campo DC
    J Drugs Dermatol; 2021 Oct; 20(10):1117-1119. PubMed ID: 34636515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent generalized pustular psoriasis possibly triggered by apremilast.
    Wang WM; Shu D; Jiang YY; Jin HZ
    Chin Med J (Engl); 2020 May; 133(10):1259-1260. PubMed ID: 32433065
    [No Abstract]   [Full Text] [Related]  

  • 8. Acrodermatitis continua of Hallopeau: Is apremilast an efficacious treatment option?
    Megna M; Potestio L; Di Caprio N; Tajani A; Fabbrocini G; Annunziata A
    Dermatol Ther; 2022 May; 35(5):e15423. PubMed ID: 35261135
    [No Abstract]   [Full Text] [Related]  

  • 9. Biological treatment of palmoplantar pustulosis: Long-term experience in 10 patients.
    Ghazanfar MN; Jørgensen AR; Thomsen SF
    Dermatol Ther; 2021 Mar; 34(2):e14780. PubMed ID: 33449416
    [No Abstract]   [Full Text] [Related]  

  • 10. Evidence is lacking for or against palmoplantar pustulosis treatments: what does this mean for the clinician.
    Feldman SR; Huang WW
    Br J Dermatol; 2021 Jun; 184(6):990. PubMed ID: 33249571
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of secukinumab-resistant palmoplantar pustulosis by Dupilumab: A case report.
    Zheng YX; Zheng M; Cai SQ
    Dermatol Ther; 2022 Nov; 35(11):e15781. PubMed ID: 35986706
    [No Abstract]   [Full Text] [Related]  

  • 12. The challenge of palmoplantar pustulosis therapy: Are Interleukin-23 inhibitors an option?
    Poortinga S; Balakirski G; Kromer C; Mössner R; Schön MP; Bieber T; Wilsmann-Theis D
    J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):e907-e911. PubMed ID: 34309915
    [No Abstract]   [Full Text] [Related]  

  • 13. Economic Burden of Palmoplantar Pustulosis in Sweden: A Population-based Register Study.
    Löfvendahl S; Norlin JM; Schmitt-Egenolf M
    Acta Derm Venereol; 2023 Jan; 103():adv00843. PubMed ID: 36621923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Treatment of Rituximab-Associated Palmoplantar Pustulosis With Apremilast in a Patient With Seropositive Rheumatoid Arthritis.
    Haller C; Cozzio A; von Kempis J; Rubbert-Roth A
    J Clin Rheumatol; 2021 Oct; 27(7):e289-e290. PubMed ID: 32453211
    [No Abstract]   [Full Text] [Related]  

  • 15. Rates of psoriasis in patients with palmoplantar pustulosis.
    Haidari W; Feldman SR
    Br J Dermatol; 2019 Nov; 181(5):887-888. PubMed ID: 31399995
    [No Abstract]   [Full Text] [Related]  

  • 16. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
    J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to 'Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)'.
    Yatsuzuka K; Murakami M
    Br J Dermatol; 2022 May; 186(5):908. PubMed ID: 34878653
    [No Abstract]   [Full Text] [Related]  

  • 18. Three cases of palmoplantar pustulosis successfully treated with apremilast.
    Eto A; Nakao M; Furue M
    J Dermatol; 2019 Jan; 46(1):e29-e30. PubMed ID: 29905386
    [No Abstract]   [Full Text] [Related]  

  • 19. Immediate response to apremilast in patients with palmoplantar pustulosis: a retrospective pilot study.
    Kato N; Takama H; Ando Y; Yanagishita T; Ohshima Y; Ohashi W; Akiyama M; Watanabe D
    Int J Dermatol; 2021 May; 60(5):570-578. PubMed ID: 33454961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alitretinoin therapy for palmoplantar pustulosis.
    Brunasso AMG; Massone C
    Br J Dermatol; 2017 Aug; 177(2):578-579. PubMed ID: 28444951
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.